Hepatocellular carcinoma: Concomitant sorafenib promotes necrosis after radiofrequency ablation - Propensity score matching analysis

Radiology

Volumn 272, Issue 2, 2014, Pages 598-604

  Fukuda, Hiroyuki ^a   Numata, Kazushi ^a   Moriya, Satoshi ^a   Shimoyama, Yu ^a   Ishii, Tomohiro ^a   Nozaki, Akito ^a   Kondo, Masaaki ^a   Morimoto, Manabu ^a   Maeda, Shin ^a   Sakamaki, Kentaro ^a   Morita, Satoshi ^a   Tanaka, Katsuaki ^a  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; EQUIPMENT DESIGN; FEMALE; HUMAN; LIVER CELL CARCINOMA; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROPENSITY SCORE; RADIOFREQUENCY ABLATION; RADIOFREQUENCY ABLATION DEVICE; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR NECROSIS; TUMOR VOLUME; VERY ELDERLY; CANCER CHEMOTHERAPY; CANCER SIZE; CANCER SURGERY; CHILD PUGH SCORE; COMPARATIVE EFFECTIVENESS; DRUG APPROVAL; DRUG SAFETY; MAJOR CLINICAL STUDY; NECROSIS; NEEDLE SIZE; PROPENSITY SCORE MATCHING ANALYSIS; STATISTICAL ANALYSIS;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COMBINED MODALITY THERAPY; CONTRAST MEDIA; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NECROSIS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROPENSITY SCORE; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84986903157     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14131640     Document Type: Article

References (32)

1. Seki T, Wakabayashi M, Nakagawa T, et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 1994;74(3):817-825. (Pubitemid 24237460)
2. McGahan JP, Browning PD, Brock JM, Tesluk H. Hepatic ablation using radiofrequency electrocautery. Invest Radiol 1990;25(3):267-270. (Pubitemid 20085776)
3. Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am 1995;1(1):73-81.
4. Goldberg SN, Solbiati L, Hahn PF, et al. Large-volume tissue ablation with radio frequency by using a clustered, internally cooled electrode technique: laboratory and clinical experience in liver metastases. Radiology 1998;209(2):371-379. (Pubitemid 28503101)
5. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radiofrequency ablation versus ethanol injection. Radiology 1999;210(3):655-661. (Pubitemid 29124024)
6. Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000;232(3):381-391.
7. Izumi N, Asahina Y, Noguchi O, et al. Risk factors for distant recurrence of hepatocellular carcinoma in the liver after complete coagulation by microwave or radiofrequency ablation. Cancer 2001;91(5):949-956.
8. Kim YS, Rhim H, Cho OK, Koh BH, Kim Y. Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: analysis of the pattern and risk factors. Eur J Radiol 2006;59(3):432-441. (Pubitemid 44301741)
9. Chinn SB, Lee FT Jr, Kennedy GD, et al. Effect of vascular occlusion on radiofrequency ablation of the liver: results in a porcine model. AJR Am J Roentgenol 2001;176(3):789-795. (Pubitemid 32181988)
10. Bilchik AJ, Wood TF, Allegra D, et al. Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: a proposed algorithm. Arch Surg 2000;135(6):657-662; discussion 662-664.
11. Goldberg SN, Hahn PF, Halpern EF, Fogle RM, Gazelle GS. Radio-frequency tissue ablation: effect of pharmacologic modulation of blood flow on coagulation diameter. Radiology 1998;209(3):761-767. (Pubitemid 28564911)
12. Patterson EJ, Scudamore CH, Owen DA, Nagy AG, Buczkowski AK. Radiofrequency ablation of porcine liver in vivo: effects of blood flow and treatment time on lesion size. Ann Surg 1998;227(4):559-565. (Pubitemid 28363274)
13. Rossi S, Garbagnati F, Lencioni R, et al. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 2000;217(1):119-126. (Pubitemid 33097587)
14. Yamasaki T, Kurokawa F, Shirahashi H, Kusano N, Hironaka K, Okita K. Percutaneous radiofrequency ablation therapy for patients with hepatocellular carcinoma during occlusion of hepatic blood flow: comparison with standard percutaneous radiofrequency ablation therapy. Cancer 2002;95(11):2353-2360. (Pubitemid 35351142)
15. de Baere T, Bessoud B, Dromain C, et al. Percutaneous radiofrequency ablation of hepatic tumors during temporary venous occlusion. AJR Am J Roentgenol 2002;178(1):53-59. (Pubitemid 34016370)
16. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5(10):835-844. (Pubitemid 44480537)
17. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48(4):1312-1327.
18. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48(Suppl 1):S20-S37.
19. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-390.
20. Hakimé A, Hines-Peralta A, Peddi H, et al. Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. Radiology 2007;244(2):464-470. (Pubitemid 47080878)
21. Mertens JC, Martin IV, Schmitt J, et al. Multikinase inhibitor sorafenib transiently promotes necrosis after radiofrequency ablation in rat liver but activates growth signals. Eur J Radiol 2012;81(7):1601-1606.
22. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70(1):41-45.
23. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53(3):1020-1022.
24. Morimoto M, Numata K, Kondo M, et al. Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. Hepatol Res 2011;41(4):296-302.
25. Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1000 cases. Cancer 2005;103(6):1201-1209. (Pubitemid 40328091)
26. Ebara M, Okabe S, Kita K, et al. Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. J Hepatol 2005;43(3):458-464. (Pubitemid 41111427)
27. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17(19):2265-2281.
28. Austin PC, Mamdani MM. A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med 2006;25(12):2084-2106. (Pubitemid 43950281)
29. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 2007;26(4):734-753. (Pubitemid 46206593)
30. Ikeda K, Kobayashi M, Saitoh S, et al. Cost-effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3cm or less in diameter. Hepatol Res 2005;33(3):241-249. (Pubitemid 41794213)
31. Ishii H, Okada S, Nose H, et al. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer 1996;77(9):1792-1796. (Pubitemid 26125178)
32. Hines-Peralta A, Sukhatme V, Regan M, Signoretti S, Liu ZJ, Goldberg SN. Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models. Radiology 2006;240(1):82-89. (Pubitemid 43902597)